Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Genentech Inc
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
Study comparing MHAA4549A in combination with oseltamivir versus placebo in combination with oseltamivir for the treatment of severe influenza A infection
to determine the time to normalization of respiratory function of patients dosed with MHAA4549A in combination with oseltamivir compared to patients dosed with placebo and oseltamivir.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE
• To evaluate the safety of MPSK3169A on top of standard-of-care (SOC) statin in patients with an low-density lipoprotein cholesterol (LDL-c) of 90−250 mg/dL and either coronary heart disease (CHD) or...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
Study of the investigational drug MEHD7945A compared to the anticancer drug cetuximab when combined with standard chemotherapy in patients with colorectal cancer without mutation in the KRAS gene (Kras wild type)
1-To evaluate the efficacy, as measured by PFS, of FOLFIRI + MEHD7945A (administered every 2 weeks) versus FOLFIRI + cetuximab (administered weekly) in patients with KRAS wild-type mCRC 2- To eval...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869g AND ABE4955g IN PATIENTS WITH MILD TO MODERATE ALZHEIMER?S DISEASE ESTUDIO MULTICÉNTRICO, ABIERTO, DE EXTENSIÓN A LARGO PLAZO SOBRE SEGURIDAD DE LOS ESTUDIOS EN FASE II ABE4869g Y ABE4955g EN PACIENTES CON ENFERMEDAD DE ALZHEIMER ENTRE LEVE Y MODERADA
To assess the long-term safety and tolerability of crenezumab administered subcutaneously (SC) every 2 weeks (q2w) or intravenously (IV) every 4 weeks (q4w), in eligible patients with Alzheimer?s dise...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
A clinical study comparing the effects of chemotherapy plus Avastin to chemotherapy plus Avastin plus a new drug (MEGF0444A) in patients with colorectal cancer that has spread to other parts of the body, who have not received chemotherapy before
To estimate the efficacy of MEGF0444A used in combination with FOLFOX + bevacizumab therapy in patients with previously untreated mCRC, as measured by progression-free survival (PFS)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
UN ENSAYO DE FASE II, MULTICÉNTRICO, ALEATORIZADO, DOBLE-CIEGO, CONTROLADO POR PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE GDC-0449 COMO TERAPIA DE MANTENIMIENTO EN PACIENTES CON CÁNCER OVÁRICO EN UNA SEGUNDA O TERCERA REMISIÓN COMPLETA A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN A SECOND OR THIRD COMPLETE REMISSION
El objetivo primario de este estudio es: - Estimar el beneficio clínico de la adición de GDC-0449 como terapia de mantenimiento para pacientes con cáncer ovárico en una segunda o tercera remisión comp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
A clinical trial of MABT5102A for the treatment of Alzheimer's Disease Un ensayo clínico de MABT5102A para el tratamiento de la Enfermedad de Alzheimer
?To evaluate the efficacy of MABT5102A compared with placebo, when administered over 68 weeks to patients with mild to moderate AD, in inhibiting disease progression using the Alzheimer?s Disease Asse...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
To test whether the experimental drug GDC-0449 is safe and effective for advanced basal cell carcinoma
The primary objective of this study is - to estimate the clinical benefit of Vismodegib given as therapy for patients with locally advanced or metastatic BCC, as measured by overall response rate (O...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
A Study examining the treatment effect and Safety of GDC-0853 when compared With Placebo and a biologic therapy (Adalimumab) in Rheumatoid Arthritis Patients who have not responded to Previous therapies
• To evaluate the efficacy and safety of GDC-0853 compared with placebo used in combination with stable doses of methotrexate (MTX) in patients (Pts) with active RA who have had an inadequate response...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genentech Inc
MAJ Il y a 4 ans
A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER LOW-GRADE, CD20, B CELL NON HODGKINS LYMPHOMAS THAT HAVE PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY
phase II: to evaluate the safety of multiple doses of Apo2L/TRAIL administered in combination with rituximab to subjects with relapsed follicular NHL who have progressed following stable disease o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
Suivant